Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2019
Price : $35 *
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 May 2015 Planned End Date changed from 1 Apr 2026 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 27 May 2015 Planned primary completion date changed from 1 Apr 2026 to 1 Jun 2015 as reported by ClinicalTrials.gov record.